The DOI matches its OpenAlex record; 10 of the 10 references it cites were found in a registry or an index.
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival
Abstract
PURPOSE: To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL). PATIENTS AND METHODS: From March 1997 to May 1999, 40 previously untreated patients with stage II through IV MCL were treated with six cycles of rituximab and CHOP chemotherapy in a phase II trial. Pretreatment and interval peripheral-blood (PB) and bone marrow (BM) specimens were also analyzed by polymerase chain reaction (PCR) for tumor-specific BCL-1/immunoglobulin H (IgH) translocations and clonal IgH rearrangements. Study end points included clinical and molecular response rates and long-term progression-free survival (PFS). RESULTS: Forty-eight percent of patients achieved a complete response (CR)/CR unconfirmed (CRu), and 48% of patients obtained a partial response (PR). However, 28 of the 40 patients have already relapsed or developed progressive disease with a median PFS of 16.6 months. Twenty-five patients had PCR-detectable BCL-1/IgH or clonal IgH products in PB or BM at diagnosis. Nine of the 25 informative patients had no evidence of PCR-detectable disease in PB or BM after rituximab and CHOP therapy. However, patients who achieved molecular remissions in PB or BM had PFS similar to patients without molecular remissions (16.5 v 18.8 months, P =.51). CONCLUSION: Favorable clinical and molecular response rates associated with rituximab and CHOP chemotherapy do not translate into prolonged PFS in MCL. Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM of detectable tumor cells, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationAvoiding false positives with PCR
Kwok, S., & Higuchi, R. (1989) · Nature · doi:10.1038/339237a0 · Cited by 3,441
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases
Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E., & Gascoyne, R. D. (1997) · Blood · doi:10.1182/blood.v89.6.2067 · Cited by 497
Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 472
Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors
Bosch, F., L�pez-Guillermo, A., Campo, E., Ribera, J. M., Conde, E., Piris, M. A., Vallesp�, T., Woessner, S., & Montserrat, E. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980201)82:3<567::aid-cncr20>3.0.co;2-z · Cited by 346
Freedman, A. S., Neuberg, D., Gribben, J. G., Mauch, P., Soiffer, R. J., Fisher, D. C., Anderson, K. C., Andersen, N., Schlossman, R., Kroon, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.13 · Cited by 184
Self-citation
Cited by
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147025 · Cited by 622
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Treatment of Older Patients with Mantle-Cell Lymphoma
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200920 · Cited by 520
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Rituximab: A Review of its Use in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukaemia
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
Rummel, M. J., Al-Batran, S. E., Kim, S.-Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.-M., Dürk, H., Rost, A., Neise, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.100 · Cited by 441
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8435 · Cited by 399
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0021 · Cited by 329
Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2013) · American Journal of Hematology · doi:10.1002/ajh.23615 · Cited by 328
Monoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Dreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., Kluin-Nelemans, J. C., Ladetto, M., Le Gouill, S., Iannitto, E., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds643 · Cited by 311
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Boye, J., Elter, T., & Engert, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg175 · Cited by 294
Pott, C., Hoster, E., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet-Bauchu, E., Andersen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-06-230250 · Cited by 272
Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J., Maziarz, R. T., Agura, E., Langston, A. A., Pulsipher, M., Storb, R., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2275 · Cited by 257
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Metadata
- Authors
- Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M. L., Poor, C., Janicek, M. J., & Shipp, M. A.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1288-1294
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W1996537666
- Cited by
- 372
- References
- 10
- FWCI
- 18.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.